Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy

Prostate

Volumn 71, Issue 11, 2011, Pages 1189-1197

  Huang, Shu Pin ^a,b,c   Bao, Bo Ying ^d   Wu, Ming Tsang ^a,e   Choueiri, Toni K ^f   Goggins, William B ^g   Huang, Chao Yuan ^h   Pu, Yeong Shiau ^h   Yu, Chia Cheng ⁱ   Huang, Chun Hsiung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

ⁱ KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

androgen deprivation therapy; metastatic prostate cancer; prostate cancer; prostate specific antigen kinetics; prostate specific antigen nadir; time to prostate specific antigen nadir

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 79958216381     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21334     Document Type: Article

References (40)

1. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ,. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-424. (Pubitemid 19211484)
2. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA,. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-1042. (Pubitemid 28457865)
3. Sharifi N, Gulley JL, Dahut WL,. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-244. (Pubitemid 41043794)
4. Kelly WK, Scher HI,. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 1993; 149: 607-609. (Pubitemid 23094069)
5. Small EJ, Srinivas S,. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995; 76: 1428-1434.
6. Small EJ, Vogelzang NJ,. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 1997; 15: 382-388. (Pubitemid 27021526)
7. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ,. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-1237. (Pubitemid 46606398)
8. Scher HI, Kelly WM, Zhang ZF, Ouyang P, Sun M, Schwartz M, Ding C, Wang W, Horak ID, Kremer AB,. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 1999; 91: 244-251. (Pubitemid 29090993)
9. Shulman MJ, Benaim EA,. The natural history of androgen independent prostate cancer. J Urol 2004; 172: 141-145. (Pubitemid 41615056)
10. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW,. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972-3982.
11. D'Amico AV, Chen MH, Roehl KA, Catalona WJ,. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-135.
12. D'Amico AV, Renshaw AA, Sussman B, Chen MH,. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 440-447. (Pubitemid 41124176)
13. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV,. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005; 23: 6992-6998.
14. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. (Pubitemid 28445094)
15. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE,. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002; 168: 995-1000.
16. Benaim EA, Pace CM, Lam PM, Roehrborn CG,. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 2002; 59: 73-78. (Pubitemid 34059310)
17. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV,. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005; 23: 6556-6560. (Pubitemid 46190248)
18. Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK,. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009; 115: 981-987.
19. Huang SP, Chou YH, Wayne Chang WS, Wu MT, Chen YY, Yu CC, Wu TT, Lee YH, Huang JK, Wu WJ, Huang CH,. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett 2004; 207: 69-77. (Pubitemid 38429888)
20. Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, Huang CH,. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 2217-2224. (Pubitemid 40054320)
21. Huang SP, Huang CY, Wu WJ, Pu YS, Chen J, Chen YY, Yu CC, Wu TT, Wang JS, Lee YH, Huang JK, Huang CH, Wu MT,. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer 2006; 119: 1902-1907. (Pubitemid 44356849)
22. Huang SP, Huang CY, Wang JS, Liu CC, Pu YS, Yu HJ, Yu CC, Wu TT, Huang CH, Wu WJ, Chou YH, Wu MT,. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res 2007; 13: 6632-6638. (Pubitemid 350206798)
23. Huang SP, Huang CY, Liu CC, Yu CC, Pu YS, Chueh SC, Yu HJ, Wu TT, Li CC, Huang CH, Wu WJ,. Clinical outcome of Taiwanese men with clinically localized prostate cancer post-radical prostatectomy: A comparison with other ethnic groups. Aging Male 2010; 13: 10-17.
24. Huang SP, Huang LC, Ting WC, Chen LM, Chang TY, Lu TL, Lan YH, Liu CC, Yang WH, Lee HZ, Hsieh CJ, Bao BY,. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2009; 18: 3068-3074.
25. Huang SP, Ting WC, Chen LM, Huang LC, Liu CC, Chen CW, Hsieh CJ, Yang WH, Chang TY, Lee HZ, Bao BY,. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol 2009; 17: 312-322.
26. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M,. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008; 26: 842-847. (Pubitemid 351398074)
27. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-1605. (Pubitemid 46733088)
28. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH,. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005; 23: 6139-6148.
29. Collette L, de Reijke TM, Schroder FH,. Prostate specific antigen: A prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 2003; 44: 182-189; discussion 9. (Pubitemid 36917001)
30. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D,. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 3984-3990. (Pubitemid 46630748)
31. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK,. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: Association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008; 112: 1247-1253. (Pubitemid 351429739)
32. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516-521. (Pubitemid 43898814)
33. Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M,. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993; 42: 119-129; discussion 29-30.
34. Mulders PF, Fernandez del Moral P, Theeuwes AG, Oosterhof GO, van Berkel HT, Debruyne FM,. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol 1992; 21: 2-5.
35. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI,. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999; 91: 1869-1876.
36. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C,. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105: 12182-12187.
37. Taplin ME,. Androgen receptor: Role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther 2008; 8: 1495-1508.
38. Yuan X, Balk SP,. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009; 27: 36-41.
39. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80. (Pubitemid 350166735)
40. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.